Pharsight

Mavyret patents expiration

MAVYRET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648037 ABBVIE Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(7 years from now)

US8937150 ABBVIE Anti-viral compounds
May, 2032

(7 years from now)

USRE48923 ABBVIE Crystal forms
May, 2035

(10 years from now)

US9321807 ABBVIE Crystal forms
Jun, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE Anti-viral compounds
Jun, 2030

(5 years from now)

US10039754 ABBVIE Anti-viral compounds
Jun, 2030

(5 years from now)

US9586978 ABBVIE Anti-viral compounds
Nov, 2030

(6 years from now)

US10028937

(Pediatric)

ABBVIE Anti-viral compounds
Dec, 2030

(6 years from now)

US10039754

(Pediatric)

ABBVIE Anti-viral compounds
Dec, 2030

(6 years from now)

US9586978

(Pediatric)

ABBVIE Anti-viral compounds
May, 2031

(6 years from now)

US8648037

(Pediatric)

ABBVIE Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(8 years from now)

US8937150

(Pediatric)

ABBVIE Anti-viral compounds
Nov, 2032

(8 years from now)

US10286029 ABBVIE Method for treating HCV
Mar, 2034

(9 years from now)

US11484534 ABBVIE Methods for treating HCV
Mar, 2034

(9 years from now)

US11484534

(Pediatric)

ABBVIE Methods for treating HCV
Sep, 2034

(10 years from now)

US10286029

(Pediatric)

ABBVIE Method for treating HCV
Sep, 2034

(10 years from now)

USRE48923

(Pediatric)

ABBVIE Crystal forms
Nov, 2035

(11 years from now)

US9321807

(Pediatric)

ABBVIE Crystal forms
Dec, 2035

(11 years from now)

US11246866 ABBVIE Solid pharmaceutical compositions for treating HCV
Jun, 2036

(12 years from now)

US11246866

(Pediatric)

ABBVIE Solid pharmaceutical compositions for treating HCV
Dec, 2036

(12 years from now)

Mavyret is owned by Abbvie.

Mavyret contains Glecaprevir; Pibrentasvir.

Mavyret has a total of 20 drug patents out of which 0 drug patents have expired.

Mavyret was authorised for market use on 03 August, 2017.

Mavyret is available in pellets;oral, tablet;oral dosage forms.

Mavyret can be used as treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg.

Drug patent challenges can be filed against Mavyret from 11 December, 2027.

The generics of Mavyret are possible to be released after 24 December, 2036.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-232) Apr 30, 2026
Orphan Drug Exclusivity(ODE-233) Apr 30, 2026
Orphan Drug Exclusivity(ODE-372) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028
M(M-259) Apr 10, 2023
M(M-230) Aug 06, 2021
New Patient Population(NPP) Apr 30, 2022
New Dosing Schedule(D-175) Sep 26, 2022
New Chemical Entity Exclusivity(NCE) Aug 03, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

MAVYRET family patents

Family Patents